Tubulin, the main component of microtubules, is a major target for antitumor drugs such as vinblastine. We have recently discovered that the betaII isotype of tubulin is present in the nuclei of cultured rat kidney mesangial cells, smooth-muscle-like cells present in the renal glomerular mesangium (Walss C, Kreisberg JI, Ludueña RF: Cell Motil Cytoskeleton 42: 274-284, 1999). Here, we have investigated the effect of vinblastine on nuclear betaII-tubulin in these cells. We have found that, at concentrations of 15 nM and higher, vinblastine caused a reversible loss of betaII-tubulin from the nucleus. Our results raise the possibility that nuclear betaII-tubulin constitutes a population of tubulin that could be a novel target for antitumor drugs such as vinblastine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1022947706151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nuclear βII-Tubulin and its Possible Utility in Cancer Diagnosis, Prognosis and Treatment.
Front Cell Dev Biol
May 2022
Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
Microtubules are organelles that usually occur only in the cytosol. Walss et al. (1999) discovered the βII isotype of tubulin, complexed with , in the nuclei of certain cultured cells, in non-microtubule form.
View Article and Find Full Text PDFOver-Expression of βII-Tubulin and Especially Its Localization in Cell Nuclei Correlates with Poorer Outcomes in Colorectal Cancer.
Cells
January 2019
Department of Pathology, Belarusian State Medical University, 220116 Minsk, Belarus.
Tubulin is a heterodimer of α and β subunits, both existing as isotypes differing in amino acid sequence encoded by different genes. Specific isotypes of tubulin have associations with cancer that are not well understood. Previous studies found that βII-tubulin is expressed in a number of transformed cells and that this isotype is found in cell nuclei in non-microtubule form.
View Article and Find Full Text PDFNuclear betaII-tubulin associates with the activated notch receptor to modulate notch signaling.
Cancer Res
November 2004
Graduate Institute of Cell and Molecular Biology and Graduate Institute of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan.
The Notch signal pathway plays important roles in proliferation, apoptosis, and differentiation. Abnormalities in Notch signaling are linked to many human diseases. After ligand binding, Notch signaling is activated through the cleavage of Notch receptors to release and translocate the Notch intracellular domain into the nucleus.
View Article and Find Full Text PDFThe betaII isotype of tubulin is present in the cell nuclei of a variety of cancers.
Cell Motil Cytoskeleton
February 2004
Department of Pathology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
Tubulin, the subunit protein of microtubules, has generally been thought to be exclusively a cytoplasmic protein in higher eukaryotes. We have previously shown that cultured rat kidney mesangial cells contain the betaII isotype of tubulin in their nuclei in the form of an alphabetaII dimer [Walss et al., 1999: Cell Motil.
View Article and Find Full Text PDFEffect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells.
Invest New Drugs
February 2003
Department of Biochemistry, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA.
Tubulin, the main component of microtubules, is a major target for antitumor drugs such as vinblastine. We have recently discovered that the betaII isotype of tubulin is present in the nuclei of cultured rat kidney mesangial cells, smooth-muscle-like cells present in the renal glomerular mesangium (Walss C, Kreisberg JI, Ludueña RF: Cell Motil Cytoskeleton 42: 274-284, 1999). Here, we have investigated the effect of vinblastine on nuclear betaII-tubulin in these cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!